Article

Streamlining AE Management with Automated Solutions

banner

 

Innomar Strategies delivers innovative pharmacovigilance solutions
banner

Are you finding it difficult to manage the compliance and workload demands associated with the Canada Vigilance Adverse Reaction Online Database review? If you are navigating the intricate landscape of the Canada Vigilance Adverse Reaction Online Database, you may be facing some of these challenges:

  • Frequency: Managing monthly consultations
  • Workload: Handling a high volume of Adverse Event (AE) reports
  • Timeline: Meeting the 15-day reporting deadline to foreign regulatory authorities
  • Resourcing: Limited staff and budget constraints
banner

To address these challenges, Innomar Strategies has developed an innovative automated tool designed to streamline your AE report reconciliation process. This technology generates XML files for adverse reaction reports with meticulous precision and speed.

Once created, these XML files are ready for immediate import into your safety database, significantly reducing manual workload and preserving accuracy in data reporting.

Benefits:

  • Efficient process: By automating labour-intensive tasks such as data entry, MedDRA coding, and narrative creation for AE reports, Innomar’s solution reduces the time spent on manual processes. The resulting XML files are ready to import into the safety database, allowing your team to focus on more strategic initiatives while maintaining consistency in data reporting. 
  • Compliance: Innomar’s tool meets Health Canada’s validation requirements and operates within a robust SOP-driven process for XML creation. Since its implementation, it has been routinely used for processing Canada Vigilance Adverse Reaction Reports across more than 40 products. This extensive experience underscores our commitment to excellence and our ability to deliver results that consistently meet stringent regulatory demands.
  • Flexible resources and expertise: When you work with Innomar Strategies, you have access to flexible resources to support your needs. Our team includes over 100 pharmacovigilance professionals with extensive healthcare backgrounds, such as physicians, nurses, and pharmacists. 
    By integrating our automated tool into your pharmacovigilance processes, you can better manage Canada Vigilance Adverse Reaction Reports volume and regulatory compliance while optimizing resource allocation. This comprehensive solution is meticulously designed to keep you ahead in an ever-evolving regulatory landscape.
 
By integrating our automated tool into your pharmacovigilance processes, you can better manage Canada Vigilance Adverse Reaction Reports volume and regulatory compliance while optimizing resource allocation. This comprehensive solution is meticulously designed to keep you ahead in an ever-evolving regulatory landscape.
 
The contents of this piece contain marketing statements and do not include business or legal advice.

 

Related resources

Article

How to prepare for the unannounced FDA compliance inspection

Article

Insights from Pharma 2025: Ready or not? Preparing for the EU HTA wave

Webinar

How full pharmacovigilance outsourcing increases efficiency and accuracy
To learn more about how Innomar’s pharmacovigilance team can support you with AE management, contact us today!
abstract

Cencora.com is providing automated translations to assist in reading the website in languages other than English. For these translations, reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace human translators. These translations are provided as a service to users of Cencora.com and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any of these translations made from English into any other language. Some content (such as images, videos, Flash, etc.) may not be accurately translated due to the limitations of the translation software.

Any discrepancies or differences created in translating this content from English into another language are not binding and have no legal effect for compliance, enforcement, or any other purpose. If any errors are identified, please contact us. If any questions arise related to the accuracy of the information contained in these translations, please refer to the English version of the page.